Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 1,638: | Line 1,638: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018- | "timestamp" : "2018-10-18T16:42:58Z", | ||
"briefDesignDescription" : "Rivaroxaban, ASA, or both in stable CAD", | "briefDesignDescription" : "Rivaroxaban, ASA, or both in stable CAD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1709118", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1709118", | ||
| Line 1,644: | Line 1,644: | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709118", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709118", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : "Eikelboom JW <i>et al</i>. \"Rivaroxaban with or without aspirin in stable cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. | "citation" : "Eikelboom JW <i>et al</i>. \"Rivaroxaban with or without aspirin in stable cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. 377(14):1319-1330.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "Cardiovascular Outcomes for People Using Anticoagulation Stratgies", | "expansion" : "Cardiovascular Outcomes for People Using Anticoagulation Stratgies", | ||
| Line 6,348: | Line 6,348: | ||
"title" : "Transfusion strategies for acute upper gastrointestinal bleeding", | "title" : "Transfusion strategies for acute upper gastrointestinal bleeding", | ||
"pmid" : "23281973" | "pmid" : "23281973" | ||
}, | |||
{ | |||
"timestamp" : "2018-10-18T17:42:04Z", | |||
"briefDesignDescription" : "Rivaroxaban in high-risk APLS", | |||
"fulltexturl" : "https://doi.org/10.1182/blood-2018-04-848333", | |||
"pageid" : 3700, | |||
"pdfurl" : null, | |||
"trainingLevel" : "Fellow", | |||
"citation" : "Pengo V, <i>et al</i>. \"Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome\". <i>Blood</i>. 2018. 132(13):1365-1371.", | |||
"subspecialties" : "Hematology;Rheumatology", | |||
"expansion" : "Trial on Rivaroxaban in AntiPhospholipid Syndrome", | |||
"statusUsableDate" : "2018-10-19", | |||
"briefResultsDescription" : "Rivaroxaban inferior to warfarin in high-risk APLS", | |||
"published" : "2018-09-27", | |||
"pageName" : "TRAPS", | |||
"diseases" : "Antiphospholipid Syndrome", | |||
"abbreviation" : "TRAPS", | |||
"title" : "Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome", | |||
"pmid" : "30002145" | |||
}, | }, | ||
{ | { | ||